Back to Search
Start Over
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
- Source :
- The Lancet Haematology; May 2024, Vol. 11 Issue: 5 pe324-e335, 12p
- Publication Year :
- 2024
-
Abstract
- Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 11
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs65961902
- Full Text :
- https://doi.org/10.1016/S2352-3026(24)00065-6